Transcriptional effects of Lu-octreotate therapy using a priming treatment schedule on GOT1 tumor in nude mice.

EJNMMI Res

Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy at University of Gothenburg, Gula Stråket 2B, Sahlgrenska University Hospital, SE-413 45, Gothenburg, Sweden.

Published: March 2019

AI Article Synopsis

  • Lu-octreotate therapy shows promise for neuroendocrine tumors but rarely achieves complete remission, warranting exploration of treatment schedules to enhance efficacy.
  • Previous research indicates that a priming dose of Lu-octreotate before a main injection increases tumor drug concentration, leading to better tumor reduction and prolonged regrowth periods.
  • This study utilized RNA microarray analysis to reveal that the priming treatment triggered significant transcriptional changes in tumor cells, showing unique regulatory pathways that promote cell cycle arrest and apoptosis, compared to traditional monotherapy.

Article Abstract

Background: Lu-octreotate is used for therapy of somatostatin receptor expressing neuroendocrine tumors with promising results, although complete tumor remission is rarely seen. Previous studies on nude mice bearing the human small intestine neuroendocrine tumor, GOT1, have shown that a priming injection of Lu-octreotate 24 h before the main injection of Lu-octreotate resulted in higher Lu concentration in tumor, resulting in increased absorbed dose, volume reduction, and time to regrowth. To our knowledge, the cellular effects of a priming treatment schedule have not yet been studied. The aim of this study was to identify transcriptional changes contributing to the enhanced therapeutic response of GOT1 tumors in nude mice to Lu-octreotate therapy with priming, compared with non-curative monotherapy.

Results: RNA microarray analysis was performed on tumor samples from GOT1-bearing BALB/c nude mice treated with a 5 MBq priming injection of Lu-octreotate followed by a second injection of 10 MBq of Lu-octreotate after 24 h and killed after 1, 3, 7, and 41 days after the last injection. Administered activity amounts were chosen to be non-curative, in order to facilitate the study of tumor regression and regrowth. Differentially regulated transcripts (RNA samples from treated vs. untreated animals) were identified (change ≥ 1.5-fold; adjusted p value < 0.01) using Nexus Expression 3.0. Analysis of the biological effects of transcriptional regulation was performed using the Gene Ontology database and Ingenuity Pathway Analysis. Transcriptional analysis of the tumors revealed two stages of pathway regulation for the priming schedule (up to 1 week and around 1 month) which differed distinctly from cellular responses observed after monotherapy. Induction of cell cycle arrest and apoptotic pathways (intrinsic and extrinsic) was found at early time points after treatment start, while downregulation of pro-proliferative genes were found at a late time point.

Conclusions: The present study indicates increased cellular stress responses in the tumors treated with a priming treatment schedule compared with those seen after conventional Lu-octreotate monotherapy, resulting in a more profound initiation of cell cycle arrest followed by apoptosis, as well as effects on PI3K/AKT-signaling and unfolded protein response.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426909PMC
http://dx.doi.org/10.1186/s13550-019-0500-2DOI Listing

Publication Analysis

Top Keywords

nude mice
16
lu-octreotate therapy
12
injection lu-octreotate
12
therapy priming
8
priming treatment
8
treatment schedule
8
priming injection
8
lu-octreotate 24 h
8
lu-octreotate
7
tumor
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!